Core Viewpoint - The company has adjusted the grant price for its restricted stock incentive plan in response to the upcoming dividend distribution in 2025, ensuring compliance with relevant laws and regulations [1] Summary by Relevant Sections - Incentive Plan Adjustment The company has received necessary approvals for its 2024 restricted stock incentive plan adjustment, with the grant price reduced from 13.68 yuan per share to 13.10 yuan per share [1] - Approval Process Multiple board and supervisory meetings were held from March 2024 to September 2025 to review related proposals, confirming the company's adherence to procedural requirements [1] - Legal Compliance The legal opinion issued by Hunan Qiyuan Law Firm states that the adjustments made to the grant price are in line with applicable laws and the provisions of the company's incentive plan draft [1]
可孚医疗2024年限制性股票激励计划调整获法律认可